Pharmaceutical Market of Eurasian Economic Union (EEU): The Current State and Directions of Development

About the authors:

Pavel A. Nalimov, Postgraduate Student, Doctoral School of Social Sciences, University of Trento (Italy); pavel.nalimov@unitn.it

Dmitry Yu. Rudenko, Cand. Sci. (Econ.), Associate Professor, Department of World Economy and International Business, Tyumen State University; d.y.rudenko@utmn.ru

Abstract:

This article aims to formulate the concepts of the roadmap for EEU’s pharmaceutical market development in the context of national medicines coverage. The relevance of the study lies in high import dependence of national markets, despite of a number of previously undertaken and currently implemented state programs, dedicated to pharmaceutical industries formation. In the conditions, when national pharmaceutical manufacturers cannot compete with the largest foreign producers, the obvious need is not to unite the markets themselves, but to cooperate in the fields of vital drugs production and research in order to develop innovative activity. To illustrate these aspects, the authors have studied the current difficulties with EEU’s market formation, as well as the markets’ state within medicines production and consumption, in three largest EEU’s economies: Russia, Kazakhstan, and Belarus.

In conclusion, the authors suggest a roadmap proposing the gradual formation of EEU’s pharmaceutical market and deepening of its integration into the world pharmaceutical market over the next 15 years.

References:

1. Novosti GMP. “43% vsego farmatsevticheskogo rynka Kazakhstana sostavlyayet gosudarstvennyy zakaz” [43% of All the Farmaceutical Market in Kazakhstan Constitutes State Commissions]. http://gmpnews.ru/2015/07/43-vsego-farmacevticheskogo-rynka-kazaxstana-sostavlyaet-gosudarstvennyj-z...
2. Farmatsevticheskiy vestnik. “Dolya otechestvennykh lekarstv v belorusskikh bolnitsakh sostavlyayet 80%” [The Share of Domestic Medicines in Belarusian Hospitals Is 80%]. Farmatsevticheskiy vestnik. http://www.pharmvestnik.ru/publs/lenta/v-mire/dolja-otechestvennyx-lekarstv-v-belorusskix-boljnitsax...
3. Evraziyskaya ekonomicheskaya komissiya. Departament promyshlennoy politiki. “Informatsiya o rezultatakh analiza sostoyaniya i razvitiya farmatsevticheskoy otrasli gosudarstv-chlenov Evraziyskogo ekonomicheskogo soyuza” [Information on the Results of the Analysis of the State and Development of the Pharmaceutical Industry of the Member States of the Eurasian Economic Union]. Evraziyskaya ekonomicheskaya komissiya. Departament promyshlennoy politiki. Rabochiye materialy.
4. Kusainov A. “Obshchiy rynok lekarstvennykh sredstv EAES: pravila dostupa i konkurentsii” [General Market of Medicines of the EAEC: Rules for Access and Competition]. Onlayn zakon. http://online.zakon.kz/Document/?doc_id=38270273
5. Lin A. A.. Sokolova S. V.. Bolshakova M. V. 2016. “Farmatsevticheskiy rynok: formirovaniye edinogo prostranstva lekarstvennogo obrashcheniya stran EAES” [Pharmaceutical Market: The Formation of a Single Drug Treatment Area of the EAEU Countries]. Problemy sovremennoy ekonomiki, no 4, pp. 6-9.
6. Nalimov P. A., Rudenko D. Yu. 2015. “Mirovoy farmatsevticheskiy rynok: polyarnost globalnogo zdorovia” [The World Pharmaceutical Market: The Polarity of Global Health]. EKO (vserossiyskiy ekonomicheskiy zhurnal), no 3, pp. 116-28.
7. RF Government Decree of 15 April 2014 no 305 “Ob utverzhdenii gosudarstvennoy programmy Rossiyskoy Federatsii ‘Razvitiye farmatsevticheskoy i meditsinskoy promyshlennosti’ na 2013-2020 gody” [On Approval of the State Program of the Russian Federation “Development of the Pharmaceutical and Medical Industry” for 2013-2020]. Garant. http://www.garant.ru/products/ipo/prime/doc/70544070/
8. Rudenko D. Yu., Didenko N. I. 2016. “Mirovoy opyt otsenki urovnya nauchno-tehnologicheskogo razvitiya” [International Assessment of the Technological Development]. Tyumen State University Herald. Social, Economic, and Law Research, no 4, vol. 2, pp. 129-147. DOI: 10.21684/2411-7897-2016-2-4-129-147
9. Deloitte. “Situatsiyu s edinym rynkom lekarstvennykh sredstv kommentiruyut eksperty” [Experts Comment on the Situation with a Single Drug Market]. https://www2.deloitte.com/ru/ru/pages/about-deloitte/deloitte-in-press/2016-year/edinui-runok-lekars...
10. DSM Group. “Farmatsevticheskiy rynok Rossii” [Russian Farmaceutical Market]. http://dsm.ru/docs/analytics/september_2016_pharmacy_analysis.pdf
11. RF Federal Law of 12 April 2010 no 61-FZ “Ob obrashchenii lekarstvennykh sredstv” [On the Circulation of Medicines]. Konsultant Plyus. http://www.consultant.ru/document/cons_doc_LAW_99350/
12. Chesnokova O. “V programmu ‘farma-2020’ vlozheno 50 mlrd rubley” [50 Billion Rubles Have Been Invested into the “Pharma-2020” Program]. Informatsionnoye agentstvo Vademecum. http://www.vademec.ru/news/2016/07/13/v-realizatsiyu-programmy-farma-2020-rossiya-vlozhila-okolo-50-...